Logo image of XGN

EXAGEN INC (XGN) Stock Fundamental Analysis

NASDAQ:XGN - Nasdaq - US30068X1037 - Common Stock - Currency: USD

4.73  -0.07 (-1.46%)

Fundamental Rating

2

XGN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of XGN have multiple concerns. XGN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XGN has reported negative net income.
XGN had a negative operating cash flow in the past year.
In the past 5 years XGN always reported negative net income.
In the past 5 years XGN always reported negative operating cash flow.
XGN Yearly Net Income VS EBIT VS OCF VS FCFXGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -38.82%, XGN is in line with its industry, outperforming 57.88% of the companies in the same industry.
XGN has a Return On Equity of -131.54%. This is in the lower half of the industry: XGN underperforms 61.59% of its industry peers.
Industry RankSector Rank
ROA -38.82%
ROE -131.54%
ROIC N/A
ROA(3y)-39.45%
ROA(5y)-34.78%
ROE(3y)-82.51%
ROE(5y)-68.36%
ROIC(3y)N/A
ROIC(5y)N/A
XGN Yearly ROA, ROE, ROICXGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 200 400 600

1.3 Margins

XGN has a Gross Margin of 58.80%. This is in the better half of the industry: XGN outperforms 78.76% of its industry peers.
XGN's Gross Margin has been stable in the last couple of years.
XGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.54%
GM growth 5Y1.28%
XGN Yearly Profit, Operating, Gross MarginsXGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

2

2. Health

2.1 Basic Checks

XGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XGN has been increased compared to 1 year ago.
XGN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XGN is higher compared to a year ago.
XGN Yearly Shares OutstandingXGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
XGN Yearly Total Debt VS Total AssetsXGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -6.83, we must say that XGN is in the distress zone and has some risk of bankruptcy.
XGN has a Altman-Z score of -6.83. This is in the lower half of the industry: XGN underperforms 68.85% of its industry peers.
XGN has a Debt/Equity ratio of 1.54. This is a high value indicating a heavy dependency on external financing.
XGN has a worse Debt to Equity ratio (1.54) than 81.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Altman-Z -6.83
ROIC/WACCN/A
WACC9.37%
XGN Yearly LT Debt VS Equity VS FCFXGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M

2.3 Liquidity

XGN has a Current Ratio of 4.05. This indicates that XGN is financially healthy and has no problem in meeting its short term obligations.
XGN has a Current ratio (4.05) which is comparable to the rest of the industry.
A Quick Ratio of 4.05 indicates that XGN has no problem at all paying its short term obligations.
XGN has a Quick ratio (4.05) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.05
Quick Ratio 4.05
XGN Yearly Current Assets VS Current LiabilitesXGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

XGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.46%, which is quite impressive.
The Revenue has been growing slightly by 7.99% in the past year.
The Revenue has been growing by 10.13% on average over the past years. This is quite good.
EPS 1Y (TTM)49.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.68%
Revenue 1Y (TTM)7.99%
Revenue growth 3Y7.77%
Revenue growth 5Y10.13%
Sales Q2Q%-6.78%

3.2 Future

The Earnings Per Share is expected to grow by 13.63% on average over the next years. This is quite good.
The Revenue is expected to grow by 15.43% on average over the next years. This is quite good.
EPS Next Y32.79%
EPS Next 2Y21.96%
EPS Next 3Y18.42%
EPS Next 5Y13.63%
Revenue Next Year10.79%
Revenue Next 2Y14.89%
Revenue Next 3Y13.87%
Revenue Next 5Y15.43%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XGN Yearly Revenue VS EstimatesXGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
XGN Yearly EPS VS EstimatesXGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XGN Price Earnings VS Forward Price EarningsXGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XGN Per share dataXGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as XGN's earnings are expected to grow with 18.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.96%
EPS Next 3Y18.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXAGEN INC

NASDAQ:XGN (2/11/2025, 2:05:26 PM)

4.73

-0.07 (-1.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners47.52%
Inst Owner Change-79.78%
Ins Owners9.04%
Ins Owner Change16.7%
Market Cap83.44M
Analysts82
Price Target7.14 (50.95%)
Short Float %0.08%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.24%
Min EPS beat(2)4.4%
Max EPS beat(2)54.08%
EPS beat(4)4
Avg EPS beat(4)33.91%
Min EPS beat(4)4.4%
Max EPS beat(4)54.08%
EPS beat(8)7
Avg EPS beat(8)28.93%
EPS beat(12)10
Avg EPS beat(12)20.9%
EPS beat(16)13
Avg EPS beat(16)19.19%
Revenue beat(2)1
Avg Revenue beat(2)2.42%
Min Revenue beat(2)-8.71%
Max Revenue beat(2)13.56%
Revenue beat(4)3
Avg Revenue beat(4)7.93%
Min Revenue beat(4)-8.71%
Max Revenue beat(4)17.87%
Revenue beat(8)7
Avg Revenue beat(8)19.18%
Revenue beat(12)10
Avg Revenue beat(12)15.42%
Revenue beat(16)13
Avg Revenue beat(16)13.25%
PT rev (1m)5%
PT rev (3m)12%
EPS NQ rev (1m)3.1%
EPS NQ rev (3m)22.77%
EPS NY rev (1m)0.19%
EPS NY rev (3m)6.96%
Revenue NQ rev (1m)2.3%
Revenue NQ rev (3m)-4.27%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)-2.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.5
P/FCF N/A
P/OCF N/A
P/B 6.48
P/tB 6.48
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS3.16
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.82%
ROE -131.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.8%
FCFM N/A
ROA(3y)-39.45%
ROA(5y)-34.78%
ROE(3y)-82.51%
ROE(5y)-68.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.54%
GM growth 5Y1.28%
F-Score4
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.16%
Cap/Sales 0.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.05
Quick Ratio 4.05
Altman-Z -6.83
F-Score4
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)189.95%
Cap/Depr(5y)144.26%
Cap/Sales(3y)5.36%
Cap/Sales(5y)3.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.68%
EPS Next Y32.79%
EPS Next 2Y21.96%
EPS Next 3Y18.42%
EPS Next 5Y13.63%
Revenue 1Y (TTM)7.99%
Revenue growth 3Y7.77%
Revenue growth 5Y10.13%
Sales Q2Q%-6.78%
Revenue Next Year10.79%
Revenue Next 2Y14.89%
Revenue Next 3Y13.87%
Revenue Next 5Y15.43%
EBIT growth 1Y42.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.09%
EBIT Next 3Y25.82%
EBIT Next 5Y17.06%
FCF growth 1Y84.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.69%
OCF growth 3YN/A
OCF growth 5YN/A